Brainsway (NASDAQ:BWAY – Get Free Report)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a research note issued to investors on Monday, Benzinga reports. They presently have a $19.00 price objective on the stock. HC Wainwright’s price target suggests a potential upside of 57.74% from the stock’s previous close.
BWAY has been the subject of several other reports. LADENBURG THALM/SH SH upped their target price on Brainsway from $18.00 to $18.80 and gave the company a “buy” rating in a report on Thursday, August 13th. Wall Street Zen upgraded Brainsway from a “hold” rating to a “buy” rating in a report on Sunday, August 2nd. Weiss Ratings cut Brainsway from a “buy (b-)” rating to a “hold (c+)” rating in a report on Wednesday, August 19th. New Street Research restated a “buy” rating on shares of Brainsway in a report on Friday, July 24th. Finally, BTIG Research reiterated a “buy” rating and issued a $20.00 price objective on shares of Brainsway in a research report on Thursday, September 10th. Five equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $18.20.
Check Out Our Latest Stock Analysis on BWAY
Brainsway Trading Up 5.3%
NASDAQ:BWAY traded up $0.61 during trading hours on Monday, hitting $12.05. The company had a trading volume of 84,007 shares, compared to its average volume of 150,850. The company has a 50-day moving average of $13.71 and a 200 day moving average of $14.64. The company has a market cap of $484.81 million, a P/E ratio of 27.38 and a beta of 1.29. Brainsway has a 1 year low of $7.14 and a 1 year high of $17.40.
Brainsway (NASDAQ:BWAY – Get Free Report) last issued its earnings results on Wednesday, August 12th. The company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.10 by $0.04. The company had revenue of $17.11 million during the quarter, compared to analysts’ expectations of $16.54 million. Brainsway had a return on equity of 12.74% and a net margin of 15.65%. On average, analysts forecast that Brainsway will post 0.33 earnings per share for the current year.
Hedge Funds Weigh In On Brainsway
A number of hedge funds have recently modified their holdings of the business. Masters Capital Management LLC grew its holdings in shares of Brainsway by 65.0% during the 1st quarter. Masters Capital Management LLC now owns 1,650,000 shares of the company’s stock worth $21,928,000 after purchasing an additional 650,000 shares during the period. Renaissance Technologies LLC grew its holdings in shares of Brainsway by 87.2% during the 1st quarter. Renaissance Technologies LLC now owns 518,420 shares of the company’s stock worth $6,890,000 after purchasing an additional 241,560 shares during the period. Y.D. More Investments Ltd grew its holdings in shares of Brainsway by 136.6% during the 1st quarter. Y.D. More Investments Ltd now owns 272,004 shares of the company’s stock worth $3,615,000 after purchasing an additional 157,042 shares during the period. HWG Holdings LP purchased a new position in shares of Brainsway during the 3rd quarter worth $3,340,000. Finally, Sei Investments Co. grew its holdings in shares of Brainsway by 262.5% during the 1st quarter. Sei Investments Co. now owns 226,378 shares of the company’s stock worth $3,009,000 after purchasing an additional 163,925 shares during the period. 30.11% of the stock is currently owned by hedge funds and other institutional investors.
About Brainsway
BrainsWay Ltd. is a medical technology company that develops and commercializes noninvasive treatments for brain disorders. Its primary technology, Deep Transcranial Magnetic Stimulation (Deep TMS), uses electromagnetic fields to stimulate targeted areas of the brain and is delivered through specialized treatment systems and helmet-like coils.
The company’s Deep TMS platform is used by healthcare providers in the treatment of major depressive disorder, obsessive-compulsive disorder and smoking addiction, subject to applicable regulatory clearances and local treatment guidelines.
Further Reading
- Five stocks we like better than Brainsway
- Tesla’s Roadster Reveal Hints at 2 Much Bigger Moves
- The AI Sell-Off Continues—These 3 Stocks Keep Raising Guidance Anyway
- Mr. Wonderful’s Test for AI Data Center Stocks: Power, Permits, and Tenants
- Alcoa Beat Earnings, But Can It Escape the Aluminum Bears?
Receive News & Ratings for Brainsway Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainsway and related companies with MarketBeat.com's FREE daily email newsletter.
